Chemo-Free Maintenance Combo Promising in Pancreatic Cancer
Pairing a PARP inhibitor and immune checkpoint inhibitor together may be a viable non-cytotoxic maintenance therapy option for patients with platinum-sensitive pancreatic ductal adenocarcinoma (PDAC), according to findings of a single-center phase Ib/II study. At a median follow-up of 23.0 months, combining the PARP inhibitor niraparib (Zejula) with the anti CTLA-4 antibody ipilimumab (Yervoy) achieved […]